Lenz Therapeutics Stock Performance
| LENZ Stock | 12.88 0.09 0.69% |
The company secures a Beta (Market Risk) of 0.92, which conveys possible diversification benefits within a given portfolio. LENZ Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, LENZ Therapeutics is expected to follow. At this point, LENZ Therapeutics has a negative expected return of -0.95%. Please make sure to verify LENZ Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if LENZ Therapeutics performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days LENZ Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (0.69) | Five Day Return (9.36) | Year To Date Return (19.50) | Ten Year Return (85.29) | All Time Return (85.29) |
Last Split Factor 1:7 | Dividend Date 2024-03-21 | Last Split Date 2024-03-22 |
1 | LENZ Therapeutics Stock Price Down 5.1 percent - Time to Sell - MarketBeat | 12/23/2025 |
2 | Acquisition by Evert Schimmelpennink of 358100 shares of LENZ Therapeutics at 16.0 subject to Rule 16b-3 | 01/02/2026 |
3 | Acquisition by Shawn Olsson of 10000 shares of LENZ Therapeutics at 2.08 subject to Rule 16b-3 | 01/06/2026 |
4 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | 01/08/2026 |
5 | A Look At LENZ Therapeutics Valuation After VIZZ Launch Momentum And New Lunatus Agreement | 01/13/2026 |
6 | LENZ Therapeutics and Sarah Jessica Parker announce the launch of Make it VIZZable, the VIZZ consumer campaign | 01/14/2026 |
7 | William Blair Maintains LENZ Therapeutics With Buy Rating, Announces Target Price 58 - | 01/30/2026 |
8 | Acquisition by Chevallard Daniel R. of 200000 shares of LENZ Therapeutics at 15.05 subject to Rule 16b-3 | 02/05/2026 |
9 | LENZ Therapeutics Stock Analysis Eyeing A 295 percent Upside In The Biotech Arena - DirectorsTalk Interviews | 02/13/2026 |
| Begin Period Cash Flow | 35.1 M | |
| Total Cashflows From Investing Activities | -154.5 M |
LENZ Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,570 in LENZ Therapeutics on November 17, 2025 and sell it today you would lose (1,282) from holding LENZ Therapeutics or give up 49.88% of portfolio value over 90 days. LENZ Therapeutics is currently does not generate positive expected returns and assumes 5.4935% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than LENZ, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
LENZ Therapeutics Target Price Odds to finish over Current Price
The tendency of LENZ Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.88 | 90 days | 12.88 | about 91.26 |
Based on a normal probability distribution, the odds of LENZ Therapeutics to move above the current price in 90 days from now is about 91.26 (This LENZ Therapeutics probability density function shows the probability of LENZ Stock to fall within a particular range of prices over 90 days) .
LENZ Therapeutics Price Density |
| Price |
Predictive Modules for LENZ Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as LENZ Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.LENZ Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. LENZ Therapeutics is not an exception. The market had few large corrections towards the LENZ Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold LENZ Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of LENZ Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.78 | |
β | Beta against Dow Jones | 0.92 | |
σ | Overall volatility | 5.58 | |
Ir | Information ratio | -0.14 |
LENZ Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of LENZ Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for LENZ Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| LENZ Therapeutics generated a negative expected return over the last 90 days | |
| LENZ Therapeutics has high historical volatility and very poor performance | |
| LENZ Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (49.77 M) with profit before overhead, payroll, taxes, and interest of 17.5 M. | |
| LENZ Therapeutics generates negative cash flow from operations | |
| LENZ Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: LENZ Therapeutics Stock Analysis Eyeing A 295 percent Upside In The Biotech Arena - DirectorsTalk Interviews |
LENZ Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of LENZ Stock often depends not only on the future outlook of the current and potential LENZ Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. LENZ Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 21.3 M | |
| Cash And Short Term Investments | 209 M |
LENZ Therapeutics Fundamentals Growth
LENZ Stock prices reflect investors' perceptions of the future prospects and financial health of LENZ Therapeutics, and LENZ Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LENZ Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (1.51) % | ||||
| Current Valuation | 201.8 M | ||||
| Shares Outstanding | 31.29 M | ||||
| Price To Book | 2.08 X | ||||
| Price To Sales | 23.03 X | ||||
| Gross Profit | 17.5 M | ||||
| EBITDA | (49.71 M) | ||||
| Net Income | (49.77 M) | ||||
| Total Debt | 1.38 M | ||||
| Book Value Per Share | 6.78 X | ||||
| Cash Flow From Operations | (59.39 M) | ||||
| Earnings Per Share | (2.06) X | ||||
| Market Capitalization | 403.01 M | ||||
| Total Asset | 215.3 M | ||||
| Retained Earnings | (145.01 M) | ||||
| Working Capital | 201.51 M | ||||
About LENZ Therapeutics Performance
Evaluating LENZ Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if LENZ Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LENZ Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.28) | (0.27) |
Things to note about LENZ Therapeutics performance evaluation
Checking the ongoing alerts about LENZ Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LENZ Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LENZ Therapeutics generated a negative expected return over the last 90 days | |
| LENZ Therapeutics has high historical volatility and very poor performance | |
| LENZ Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (49.77 M) with profit before overhead, payroll, taxes, and interest of 17.5 M. | |
| LENZ Therapeutics generates negative cash flow from operations | |
| LENZ Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: LENZ Therapeutics Stock Analysis Eyeing A 295 percent Upside In The Biotech Arena - DirectorsTalk Interviews |
- Analyzing LENZ Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LENZ Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining LENZ Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LENZ Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of LENZ Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LENZ Therapeutics' stock. These opinions can provide insight into LENZ Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.